Loss of RPN1 promotes antitumor immunity via PD-L1 checkpoint blockade in triple-negative breast cancer – experimental studies
Our preliminary study reveals that targeting RPN1 promotes immune suppression, providing a new potential immunotherapy strategy for TNBC. However, further research is necessary to fully elucidate and understand the specific mechanisms of RPN1 in TNBC and its potential for clinical application.
Authors
- Yang Long (ORCID: https://orcid.org/0000-0002-2445-6112)
- Mengxue Wang (ORCID: https://orcid.org/0000-0002-0756-7427)
- Xunjia Li (ORCID: https://orcid.org/0000-0002-1182-2638)
- Deyu Zuo (ORCID: https://orcid.org/0000-0001-6901-1742)
- Shengwei Li (ORCID: https://orcid.org/0000-0002-1647-1363)
- Yushen Wu (ORCID: https://orcid.org/0000-0002-6122-2593)
- Long Wang (ORCID: https://orcid.org/0009-0009-8788-9116)
- Meng Dai
- Xuedong Yin (ORCID: https://orcid.org/0009-0004-1188-1525)
- Xue Zhang (ORCID: https://orcid.org/0000-0002-1888-0566)
Institutions
- Chongqing University (CN)
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Cancer Hospital (CN)
- First People's Hospital of Chongqing (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1097/js9.0000000000002164
- Citations
- 4
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.94